Atrial Fibrillation and Premature Atrial Complexes in Patients With Ischemic Stroke: Prevalence, Characteristics and Prognosis
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 264
- 试验地点
- 1
- 主要终点
- time to death and recurrent stroke
研究概览
简要总结
The purpose of this study is to improve secondary prevention of ischemic stroke patients by
-
Estimating prevalence and the prognostic significance of frequent premature atrial complexes in ischemic stroke patients in relation to death, recurrent stroke and atrial fibrillation.
-
Characterize ischemic stroke patients by
-
Echocardiographic characteristics
-
Biochemical markers
-
Plaque composition in the carotid arteries
- in order to improve risk stratification.
详细描述
Patients with atrial fibrillation (AF) have a five-fold increased risk of ischemic stroke compared to the general population. Identifying AF can be challenging, but prolonged rhythm monitoring of ischemic stroke patients have shown to enhance detection rates of AF. Therefore it is important to identify predictors of AF to allow targeted screening of patients after ischemic stroke and thereby reduce the recurrent stroke rate. Few former studies have shown an association between excessive numbers of premature atrial complexes (PACs) and AF.
The study population of ischemic stroke patients will at admission undergo following examinations:
- ECG
- 48 hours inpatient cardiac telemetry (If not known AF)
- 24 hours holter monitoring (if not known AF)
- echocardiogram
- blood sample
- CT scan of carotid arteries with contrast made on Dual Energy CT scan.
In the follow-up period, patients will have two visits with 48 hour holter monitoring (after 6 and 12 months, respectively) It will be noticed if patients have any recurrent events, die og developing AF.
The study population will be divided into four groups as follows:
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •admitted with ischemic stroke at a single center
- •time from diagnose to inclusion maximum 7 days.
- •written informed consent or surrogate informed consent eligible
- •age > 18 years.
排除标准
- •hemorrhagic stroke
- •terminal illness and expected lifespan of less than 6 months.
- •any physical or mental condition which make the patients unsuitable for participation in the study.
- •known with a pacemaker
- •anticoagulation treatment of other reasons than atrial fibrillation.
结局指标
主要结局
time to death and recurrent stroke
时间窗: Up to 4 years
次要结局
- Time to death, recurrent stroke and atrial fibrillation(Up to 4 years)
- Left atrial volume and function estimated by echocardiography(baseline)
研究者
Kristina Hoeg Vinther
Medical Doctor
Odense University Hospital